Skip to content
ABLD
· Euronext Paris · ISIN FR001400AHX6
Investors
Distributors
Support
Contact
Products
Products
Find by pathogen
Support
Company
Newsroom
Investors
Sustainability
Contact us
Genotyping through sequencing
DeepChek® · NGS & Sanger
Human immunodeficiency virus (HIV)
Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
Mycobacterium tuberculosis (TB)
Cytomegalovirus (CMV)
Herpes simplex virus (HSV)
Human papillomavirus (HPV)
SARS-CoV-2
RSV, BKV, Salmonella, 16S / 18S rRNA
Real-time PCR assays
UltraGene® · Detection & quantification
Respiratory infections
Gastroenteritis
Fever, rash, childhood infections
Sexually transmitted infections
Eye infections
Hepatitis
Infections of the immunosuppressed
Meningitis
Tropical fever
Software & digital
Interpretation · data · EMR
ViroScore®-HIV
DeepChek® Software & modules
MicrobioChek® · BacterioChek®
Nadis® electronic medical record
Instruments & collection
MediaChek® · OpenChek®
DNA / RNA extraction
qPCR instruments
Pipetting robots
Saliva, wastewater & surface collection kits
Browse the full catalogue
Home
/
Newsroom
/
DeepChek-HIV Whole genome Sequencing assay now…
Company news
DeepChek-HIV Whole genome Sequencing assay now CE IVD marked !
24 Jun 2022
DeepChek-HIV Whole genome Sequencing assay now CE IVD marked !
← Previous
New Distribution Partners in Georgia & Paraguay !
24 Jun 2022
Next →
ABL received CE-IVD Mark for its “UltraGene™ Assay SARS-CoV-2 PrimeChek™”
28 Jun 2022
More company news
See all
Company news
ABL Diagnostics Becomes ABL Texcell Diagnostics
18 Sept 2026 · Business Wire ↗
Company news
ABL Diagnostics Announces UltraGene Respiratory Pathogens 21 After CE-IVD Registration by ABL SA Luxembourg
27 Jul 2026 · EIN Presswire ↗
Company news
ABL Diagnostics Selected by the Évry Commercial Court to Acquire TEXCELL’s Operations
23 Jul 2026 · EIN Presswire ↗